IL23A and metabolic dysfunction-associated steatotic liver disease: Histological analysis of livers from anti-IL-23 treated Atg5 CD11cKO mice also demonstrated an improvement of NAFLD scoring and decreased hepatic fat content (Fig. 7i–k).